This study enrolled 662 patients from Fudan University Shanghai Cancer Center between 2007 and 2014, including an exploratory cohort of 512 patients with TNBC or HER2-positive breast cancer, and a validation cohort of 150 TNBC patients. This evidence concerns the gene ERBB2 and breast cancer.